Cytokinetics (CYTK) vs Praxis Precision Medicines (PRAX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Praxis Precision Medicines (PRAX) has outperformed Cytokinetics (CYTK) over the past year, gaining 434.2% versus a gain of 1.6%. Over five years, CYTK leads with a +65.7% price change compared with -7.4% for PRAX. Cytokinetics is the larger company by market cap ($8.50 billion vs $7.76 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CYTK | PRAX |
|---|---|---|
| Share price | $61.12 | $278.02 |
| Market cap | $8.50B | $7.76B |
| 1-day change | -0.37% | -0.76% |
| YTD return | -3.81% | -5.67% |
| 1-year return | +1.58% | +434.24% |
| 5-year return | +65.68% | -7.37% |
| EPS (TTM) | $-7.22 | $-12.95 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $88.04M | $0 |
| Revenue growth (YoY) | +376.56% | -100.00% |
| Net income (latest FY) | $-784.96M | $-303.27M |
| Operating margin | -695.44% | — |
| Net margin | -891.60% | — |
| 52-week high | $88.31 | $392.70 |
| 52-week low | $54.30 | $50.56 |
| Distance from 52-week high | -30.79% | -29.20% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +79.81% | +131.79% |
| Average volume | 1.95M | 404.98K |
| Shares outstanding | 139.02M | 27.92M |
| Employees | 673 | 168 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PRAX has outperformed CYTK by 432.7 percentage points over the past year.
- Cytokinetics grew revenue faster in its latest fiscal year (+376.56% vs -100.00%).
- The two companies sit in different sectors: Cytokinetics in Health Care and Praxis Precision Medicines in Healthcare.
About Cytokinetics
CYTK stock →Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM.
Health Care · Biotechnology: Pharmaceutical Preparations · 673 employees
About Praxis Precision Medicines
PRAX stock →Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide.
Healthcare · Biotechnology · 168 employees
CYTK vs PRAX FAQ
Which is bigger, Cytokinetics or Praxis Precision Medicines?
Cytokinetics (CYTK) is larger, with a market capitalization of $8.50B compared with $7.76B for Praxis Precision Medicines (PRAX).
Which stock has performed better over the past year, CYTK or PRAX?
PRAX returned +434.24% over the past 12 months, compared with +1.58% for CYTK (price return, excluding dividends). Past performance does not predict future results.
Are Cytokinetics and Praxis Precision Medicines in the same industry?
No. Cytokinetics is in the Health Care sector, while Praxis Precision Medicines is in Healthcare.